创伤后应激障碍 (PTSD) 患者的围手术期普萘洛尔
预防性、围手术期普萘洛尔对创伤后应激障碍患者围手术期和术后并发症的影响
了解哪些治疗可以促进患有创伤后应激障碍 (PTSD) 的退伍军人的围手术期护理,这对美国医疗保健系统非常重要。
PTSD 患者的特征是中枢神经系统儿茶酚胺浓度升高,以及对压力刺激的肾上腺素能反应过度和延长。 目前,尽管 PTSD 在退伍军人人群中的重要性不断上升,但尚无关于围手术期 β 受体阻滞剂治疗对 PTSD 患者影响的数据。
这项前瞻性双盲研究建议将 150 名患有 PTSD 的退伍军人随机分配到旧金山 VA 医疗中心进行骨科、胸科或血管手术的 14 天普萘洛尔或安慰剂疗程。 然后,这项研究将跟踪这些退伍军人一年,以评估干预对退伍军人手术结果的影响。
研究人员假设,随机分配到普萘洛尔组的 PTSD 患者将表现出围手术期和术后发病率和死亡率的降低。
研究概览
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
California
-
San Francisco、California、美国、94121
- San Francisco VA Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
描述
纳入标准:
- 计划在全身麻醉或联合全身麻醉下进行任何外科手术的受试者,心脏直视手术或颅内手术除外。 区域麻醉包括:1) 硬膜外麻醉,2) 蛛网膜下阻滞(脊髓),或 3) 任何区域神经阻滞
- 预计术后住院(定义为至少住院一晚)
排除标准:
如果出现以下情况,退伍军人将被排除在外:
- 他们在术前基线评估时正在接受 β 受体阻滞剂治疗
- 他们报告对普萘洛尔敏感或过敏,或有使用普萘洛尔治疗后 PTSD 恶化的病史
- 符合 AHA/ACC I 级围手术期 β 受体阻滞剂治疗(例如美托洛尔、阿替洛尔)推荐标准且不应随机分配至安慰剂组的退伍军人
- 医疗排除标准:无起搏器的高度心脏传导阻滞(所有患者均有 2 度和 3 度心脏传导阻滞)、明显的静息心动过缓(心率≤ 55 次/分钟)、血压 < 100 mmHg、未代偿性充血性心力衰竭、严重的气道过度活跃疾病和雷诺氏病
- 怀孕
- 当前使用的药物可能涉及与普萘洛尔的潜在危险相互作用
- 主要研究者认为会妨碍参与此类研究的情况(例如 医疗问题或长期随访困难)。
- 心脏直视手术和颅内手术
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:安慰剂组
|
安慰剂药丸将服用总共 14 天。 在手术当天早上,在进入手术室之前,患者将接受第一颗安慰剂药丸,每天口服一次。 在术后第 1-13 天,患者将服用一颗安慰剂药丸(每天口服一次)。 这将完成安慰剂的疗程。 |
|
实验性的:盐酸普萘洛尔
|
普萘洛尔将服用总共 14 天。 手术当天早上,在进入手术室之前,患者将接受第一剂研究药物(PDR 推荐的缓释普萘洛尔起始剂量)。 患者将在手术当天早上服用一颗 60 毫克的药丸。 在术后第 1 天,患者将服用一粒普萘洛尔 XL 80 毫克(每天口服一次)。 在术后第 2-#9 天,患者将服用一粒普萘洛尔 XL 120 毫克(每天口服一次)。 在术后第 10-11 天,患者将服用一粒普萘洛尔 XL 80 毫克(每天口服一次)。 在术后第 12-13 天,患者将服用一粒普萘洛尔 XL 60 毫克(每天口服一次)。 这将完成普萘洛尔的疗程。
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
ICU Length of Stay
大体时间:Truncated at 30 days after admission to ICU
|
Measured using patient medical records
|
Truncated at 30 days after admission to ICU
|
|
Hospital Length of Stay
大体时间:Truncated at 30 days after admission to ICU
|
Measured using patient medical records
|
Truncated at 30 days after admission to ICU
|
|
Postoperative Delirium
大体时间:Participants will be followed for the duration of hospital stay, an expected average of 1 week
|
Measured using Confusion Assessment Method (CAM-CAM-ICU)
|
Participants will be followed for the duration of hospital stay, an expected average of 1 week
|
|
Postoperative Renal Dysfunction
大体时间:Participants will be followed for the duration of hospital stay, an expected average of 1 week
|
Measured using Serum Creatinine laboratory values
|
Participants will be followed for the duration of hospital stay, an expected average of 1 week
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
围手术期并发症
大体时间:参与者将在住院期间接受随访,预计平均为 1 周
|
使用患者医疗记录进行测量
|
参与者将在住院期间接受随访,预计平均为 1 周
|
|
Pain Intensity
大体时间:12 months
|
Pain intensity was measured using a Numerical Rating Scale (NRS).
The range of the NRS is 0 and 10, where zero represents no pain at all and 10 represents the worst pain ever possible.
|
12 months
|
|
Pain Unpleasantness
大体时间:12 months
|
Measured using the Numerical Rating Scale (NRS).
The range of the NRS is 0 and 10, where zero represents no pain at all and 10 represents the worst pain ever possible.
|
12 months
|
|
Perioperative Opioids Use
大体时间:Participants will be followed from preoperative baseline to 1 year postoperative
|
Measured using patient medical records.
|
Participants will be followed from preoperative baseline to 1 year postoperative
|
|
Required Mechanical Ventilation
大体时间:Participants will be followed for the duration of hospital stay, an expected average of 1 week
|
Measured using patient medical records
|
Participants will be followed for the duration of hospital stay, an expected average of 1 week
|
|
Change in Posttraumatic Diagnostic Scale (PDS) PTSD Symptoms Severity Score
大体时间:Baseline and 12 months
|
The Posttraumatic Diagnostic Scale (PDS) Scale includes a PTSD Symptoms Severity Score ranging from 0 to 51, with higher scores indicating more severe depression.
|
Baseline and 12 months
|
|
Change in Mental Component Summary (MCS) Scores From the Short Form-36 Questionnaire (SF-36)
大体时间:Participants will be followed from preoperative baseline to 1 year postoperative
|
The Mental Component Summary (MCS) score is derived from the Short Form-36 Questionnaire (SF-36), a validated measure of health-related quality of life.
Scores range from 0 to 100, with higher scores indicating better mental health and lower scores indicating worse mental health.
|
Participants will be followed from preoperative baseline to 1 year postoperative
|
|
Change in Physical Component Summary (PCS) Scores From the Short Form-36 Questionnaire (SF-36)
大体时间:Participants will be followed from preoperative baseline to 1 year postoperative
|
The Physical Component Summary (PCS) score is derived from the Short Form-36 Questionnaire (SF-36), a validated measure of health-related quality of life.
Scores range from 0 to 100, with higher scores indicating better physical health and lower scores indicating worse physical health.
|
Participants will be followed from preoperative baseline to 1 year postoperative
|
|
Change in Pittsburgh Sleep Quality Index (PSQI) Score
大体时间:Participants will be followed from preoperative baseline to 1 year postoperative
|
The Pittsburgh Sleep Quality Index (PSQI) is a validated self-reported questionnaire assessing sleep quality.
Total scores range from 0 to 21, with higher scores indicating worse sleep quality and lower scores indicating better sleep quality
|
Participants will be followed from preoperative baseline to 1 year postoperative
|
|
Change in Beck Depression Inventory (BDI) Score
大体时间:Participants will be followed from preoperative baseline to 1 year postoperative
|
The Beck Depression Inventory (BDI) is a validated self-report measure of depressive symptoms.
Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms (worse outcome) and lower scores indicating fewer or minimal symptoms (better outcome).
|
Participants will be followed from preoperative baseline to 1 year postoperative
|
|
Postoperative Neurocognitive Dysfunction Score
大体时间:Participants will be followed from preoperative baseline to 1 year postoperative
|
The Mini-Mental State Examination (MMSE) is a widely used screening tool for cognitive function.
Total scores range from 0 to 30, with higher scores indicating better cognitive function and lower scores indicating greater cognitive impairment.
|
Participants will be followed from preoperative baseline to 1 year postoperative
|
|
30-day, 3-month, and 1-year Mortality
大体时间:Participants will be followed from preoperative baseline to 1 year postoperative
|
Measured using patient medical records
|
Participants will be followed from preoperative baseline to 1 year postoperative
|
|
Postoperative Complications
大体时间:Participants will be followed to 1 year postoperative
|
Measured using patient medical records - Composite outcome measure that included, delirium, stroke, myocardial infarction, acute kidney injury, new atrial fibrilation, infection, or congestive heart failure between the surgery and 1-yr.
|
Participants will be followed to 1 year postoperative
|
合作者和调查者
调查人员
- 首席研究员:Marek Brzezinski, M.D., Ph.D.、University of California, San Francisco
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.